安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Legal - ESMO
Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits ESMO is a Swiss-registered not-for-profit organisation All funding for this site is provided directly by ESMO Via Ginevra 4, 6900 Lugano - CH
- ESMO Interactive Guidelines
This website gives you access to the current ESMO pocket guideline titles Click on your area of interest to access the content By selecting the folder ‘Interactive Tools’ you will see all available tools such as treatment algorithms (A), medical scores (S) and calculators (C) at a glance
- How to optimise treatment in EGFR-mutant NSCLC - dailyreporter. esmo. org
Understanding and overcoming resistance mechanisms is a key strategy to maximising novel treatments for EGFR-mutant advanced non-small cell lung cancer (NSCLC), thus enabling use of agents beyond platinum chemotherapy and improving the use of first-line combinations
- New treatment options for EGFR-mutated advanced NSCLC - Daily Reporter
The study findings confirm the efficacy of the combination of amivantamab plus chemotherapy seen in the PAPILLON trial in advanced NSCLC and EGFR exon 20 insertion mutations also presented at the ESMO Congress 2023
- ESMO Breast Cancer 2023 Industry Guidelines
ESMO Breast Cancer, a multidisciplinary global meeting held in Europe, involving the top worldwide recognised experts, is the complete platform for all Breast Cancer researchers and clinicians with a specific interest in innovation, translational oncology and care esmo org ESMO BREAST CANCER Industry Guidelines
- Three new Pan-Asian-adapted guidelines at ESMO Asia Congress
At the ESMO Asia Congress 2024 (Singapore, 6-8 December), a special session offers the chance to reflect on how the management of patients with biliary tract cancers, oncogene-addicted metastatic non-small cell lung cancer (NSCLC) and epithelial ovarian cancer has evolved recently, and how to tailor the ESMO Clinical Practice Guidelines to
- EN | Non-Small-Cell Lung Cancer: Guide for Patients - esmo. org
WHA70 12 5 (22) to promote access to comprehensive and cost-effective prevention, treatment and care for the integrated management of cancers including, inter alia, increased access to affordable, safe,
- Quadruple treatment regimen in EGFR- or ALK-mutated NSCLC - Daily Reporter
The ATTLAS trial met its primary endpoint, with significantly longer PFS with ABCP than chemotherapy in patients with EGFR- or ALK-mutated NSCLC after progression on TKI therapy (ESMO Congress 2023, LBA67)
|
|
|